LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stage non-small-cell lung cancer (NSCLC)
J.D. Spicer, Shugeng Gao, Moïshe Liberman, Terufumi Kato, M. Tsuboi, SH Lee, K-N. Chen, Christophe Dooms, Margarita Majem, E. Eigendorff, Gastón Lucas Martinengo, Olivier Bylicki, M.C. Garassino, Delvys Rodríguez‐Abreu, Jamie E. Chaft, S. Novello, James Chih‐Hsin Yang, S.M. Keller, Ayman Samkari, Heather A. Wakelee
Topics & Concepts
MedicinePlaceboLung cancerInterimInterim analysisRandomizationStage (stratigraphy)Internal medicinePembrolizumabPerioperativeOncologyTolerabilityCancerClinical trialSurgeryAdverse effectPathologyHistoryBiologyPaleontologyAlternative medicineImmunotherapyArchaeologyCancer Immunotherapy and BiomarkersLung Cancer Diagnosis and TreatmentRadiomics and Machine Learning in Medical Imaging